精彩内容1月13日,国家药监局官网显示,石药集团欧意药业申报的化药1类创新药普卢格列汀片获批上市。米内网数据显示,糖尿病用药在近年中国三大终端六大市场(统计范围见文末)销售规模均超过600亿元,2024年上半年同比增长5.50%。不久前,石药集团发布公告,集团开发的1类新药SYS6041(抗体偶联药物)获批临床。普卢格列汀片是一种新型口服二肽基肽酶-IV(DPP-4)抑制剂,适用于改善成人2型...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.